Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1845-1845
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
Yuxiang Ma, Yan Huang, Yuanyuan Zhao, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 7, pp. 901-911
Closed Access | Times Cited: 30
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 25
New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3
Ioannis‐Alexios Koumprentziotis, Charalampos Theocharopoulos, Dimitra Foteinou, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 54-54
Open Access | Times Cited: 14
Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth
Anthony Cheung, Alicia M. Chenoweth, Annelie Johansson, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 15, pp. 3298-3315
Open Access | Times Cited: 11
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
Ali Hussein Mer, Yousef Mirzaei, Fatemeh Misamogooe, et al.
Drug Delivery and Translational Research (2024) Vol. 14, Iss. 11, pp. 2963-2988
Closed Access | Times Cited: 10
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Youngbo Choi, Y. Choi, Surin Hong
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 221-221
Open Access | Times Cited: 6
Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence
Mohammad Javad Khosravanian, Yousef Mirzaei, Ali Hussein Mer, et al.
Life Sciences (2024) Vol. 352, pp. 122910-122910
Closed Access | Times Cited: 6
Antibody-drug conjugates: the clinical development in gastric cancer
Yingze Zhu, Miao Zhou, Wenyue Kong, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 5
Targeting the tumour cell surface in advanced prostate cancer
Cristina Boixareu, Tarek Taha, Varadha Balaji Venkadakrishnan, et al.
Nature Reviews Urology (2025)
Closed Access
Evoking the Cancer-immunity cycle by targeting the tumor-specific antigens in Cancer immunotherapy
Xiaomeng Guo, Junqiang Bai, Xinmiao Wang, et al.
International Immunopharmacology (2025) Vol. 154, pp. 114576-114576
Closed Access
A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
Dandan Zhou, Xiao-tian Zhai, Lan-wen Zhang, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Unlocking the potential of bispecific ADCs for targeted cancer therapy
Hongye Zeng, Wenjing Ning, Xue Liu, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 4, pp. 597-621
Closed Access | Times Cited: 4
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Víctor Manuel Medina Pérez, Marta Baselga, Alberto J. Schuhmacher
Cancers (2024) Vol. 16, Iss. 15, pp. 2681-2681
Open Access | Times Cited: 4
Nanobody-based drug delivery systems for cancer therapy
Lin Liu, Bin Tu, Yao Sun, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113562-113562
Closed Access
From Bench to Bedside: Transforming Cancer Therapy with Protease Inhibitors
Alireza Shoari
Targets (2025) Vol. 3, Iss. 1, pp. 8-8
Open Access
Defeating Cancer with Armed Antibodies and Genetically Modified Immune Cells
Liang Zhao
Highlights in Science Engineering and Technology (2025) Vol. 129, pp. 57-66
Closed Access
Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome
Kevin K. Leung, Kaitlin Schaefer, Zhi Lin, et al.
Chemical Reviews (2025)
Open Access
Prospects for the Use of Antibody-Drug Conjugates in Cancer Therapy
A. O. Makarova, E. V. Svirshchevskaya, Mikhail Titov, et al.
Russian Journal of Bioorganic Chemistry (2025) Vol. 51, Iss. 2, pp. 556-573
Closed Access
Summary and Future Directions of Antibody-Drug Conjugates
Jennica L. Zaro, Jeffery Wang, Wei-Chiang Shen
AAPS advances in the pharmaceutical sciences series (2025), pp. 275-296
Closed Access
Targeted therapies against breast cancer: Clinical perspectives, obstacles and new opportunities
Diksha Nagpal, Ravinder Verma, Vineet Mittal, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 89, pp. 105049-105049
Closed Access | Times Cited: 8
Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy
Joshua Hurwitz, Lucy Haggstrom, Elgene Lim
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2017-2017
Open Access | Times Cited: 7
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
Jeremy D. Rubinstein, Maureen M. O’Brien
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top